Alpha DNA Investment Management LLC Acquires Shares of 8,147 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Alpha DNA Investment Management LLC acquired a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCIFree Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 8,147 shares of the biopharmaceutical company’s stock, valued at approximately $583,000.

A number of other large investors have also recently made changes to their positions in the business. Los Angeles Capital Management LLC increased its holdings in Intra-Cellular Therapies by 2.5% during the third quarter. Los Angeles Capital Management LLC now owns 15,364 shares of the biopharmaceutical company’s stock worth $800,000 after buying an additional 371 shares during the last quarter. Arizona State Retirement System increased its holdings in Intra-Cellular Therapies by 2.1% during the third quarter. Arizona State Retirement System now owns 24,581 shares of the biopharmaceutical company’s stock worth $1,280,000 after buying an additional 495 shares during the last quarter. Barclays PLC increased its holdings in Intra-Cellular Therapies by 51.5% during the third quarter. Barclays PLC now owns 63,688 shares of the biopharmaceutical company’s stock worth $3,318,000 after buying an additional 21,643 shares during the last quarter. Quantbot Technologies LP increased its holdings in Intra-Cellular Therapies by 22.5% during the third quarter. Quantbot Technologies LP now owns 10,602 shares of the biopharmaceutical company’s stock worth $552,000 after buying an additional 1,946 shares during the last quarter. Finally, Great Lakes Advisors LLC purchased a new stake in Intra-Cellular Therapies during the third quarter worth about $7,881,000. 92.33% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Sharon Mates sold 40,712 shares of the firm’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $66.50, for a total transaction of $2,707,348.00. Following the transaction, the chief executive officer now owns 1,050,309 shares in the company, valued at $69,845,548.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Intra-Cellular Therapies news, CEO Sharon Mates sold 40,712 shares of Intra-Cellular Therapies stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $66.50, for a total value of $2,707,348.00. Following the transaction, the chief executive officer now owns 1,050,309 shares in the company, valued at $69,845,548.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Lawrence J. Hineline sold 10,121 shares of Intra-Cellular Therapies stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $65.96, for a total value of $667,581.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 98,325 shares of company stock worth $6,504,426. Company insiders own 3.40% of the company’s stock.

Intra-Cellular Therapies Stock Performance

ITCI stock traded up $1.59 during midday trading on Friday, reaching $67.24. The company’s stock had a trading volume of 1,046,047 shares, compared to its average volume of 761,775. The stock has a fifty day simple moving average of $68.79 and a two-hundred day simple moving average of $67.54. Intra-Cellular Therapies, Inc. has a 1 year low of $45.50 and a 1 year high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCIGet Free Report) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. The business had revenue of $144.90 million for the quarter, compared to analyst estimates of $141.41 million. Intra-Cellular Therapies had a negative return on equity of 18.49% and a negative net margin of 21.57%. The business’s revenue was up 52.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.46) earnings per share. Analysts predict that Intra-Cellular Therapies, Inc. will post -0.53 earnings per share for the current year.

Wall Street Analyst Weigh In

ITCI has been the subject of a number of research reports. Canaccord Genuity Group increased their target price on shares of Intra-Cellular Therapies from $100.00 to $107.00 and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. Robert W. Baird increased their target price on shares of Intra-Cellular Therapies from $83.00 to $103.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $120.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday, April 24th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Intra-Cellular Therapies in a research report on Tuesday, May 7th. Finally, Bank of America increased their target price on shares of Intra-Cellular Therapies from $82.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $90.17.

Read Our Latest Research Report on Intra-Cellular Therapies

Intra-Cellular Therapies Profile

(Free Report)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

See Also

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.